EvaluatePharma

Report: Global medtech sales forecast to reach $522B by 2022

Tuesday, September 26, 2017

The “EvaluateMedTech World Preview 2017, Outlook to 2022” report from life science commercial intelligence firm Evaluate, reveals Medtronic was the leading medtech company in 2016 with sales of almost $30 billion and will retain the crown in 2022, with sales forecast to reach $37.7 billion. Abbott to jump to 3rd place as its acquisition of St. Jude creates the world’s second largest cardiology company.

[Read More]

Fastest drug developers and their practices

Tuesday, August 1, 2017

Drug development is a long and costly process, and companies struggle with efforts to compress cycle times and reduce costs. A new CenterWatch analysis of new molecular entities (NMEs) approved by the FDA from 2014 through 2016 shows no signs of dramatic, industry-wide improvement. Sponsors interviewed by CenterWatch cited multiple factors that influence the speed of their development programs. In particular, the selection of investigative sites and vendors (including CROs), and the relationships forged with them, were an important focus of companies seeking to improve the speed and efficiency of clinical trials.

[Read More]

Report: Higher M&A activity and investor cash expected in 2017

Friday, December 9, 2016

Despite the uncertainty that loomed over the pharma and biotech sectors with unexpected outcomes from both the U.S. presidential election and U.K.’s vote to leave the EU, 2017 may bring renewed energy to the industry with potential for more corporate activity and cash flow. According to EP Vantage, the editorial branch of the market intelligence firm Evaluate, the Trump victory may lead to a slew of business-friendly initiatives, based on the predicted lessening of political scrutiny towards drug pricing. The report shows that although the issue of drug pricing is not going away, 2017 will start with a flush of new confidence for investors, and a possible uptick in mergers and acquisitions.

[Read More]

Report: 2015 broke R&D records

Monday, May 23, 2016

The Biotechnology Innovation Organization (BIO) has released a new report, “Emerging Therapeutic Company Investment and Deal Trends,” highlighting 10 years (2006-2015) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers clinical pipeline snapshots to provide context on the degree of industry partnering and the contribution of emerging companies.

[Read More]

Welcoming procurement onto the team

Sunday, May 15, 2016

For decades, procurement professionals have been the Rodney Dangerfields of the pharmaceutical industry: they got no respect. Procurement held up projects, got bogged down in protracted budget and contract negotiations, and was a hassle.

[Read More]

Logistics issues in clinical trials

Monday, March 14, 2016

The Pulse on Global Trials by Matthew Howes

Most industry experts estimate that supply chain logistics for clinical trials account for 20 to 25% of total R&D costs. There is evidence that those estimates are growing. EvaluatePharma reports that logistics services are experiencing a growth rate of 12%, which is faster than the more stable overall market growth of 2 to 2.5%. With rising cost pressures from payers and policy makers worldwide, it is surprising that more attention has not been paid to this increasingly dominant factor in clinical development.

[Read More]

Orphan drugs cost 13.8 times more per patient

Thursday, November 5, 2015

With 2020 worldwide sales forecast at $178 billion, the orphan drug market is expected to grow by 11.7% per year (CAGR 2015 to 2020), nearly doubling the yearly growth of the overall prescription drug market. Moreover, worldwide orphan drug sales will account for 20.2% of worldwide prescription sales by 2020 (excluding generics) according to the “EvaluatePharma Orphan Drug Report 2015” from life science market intelligence firm Evaluate.

[Read More]